AI steps up in healthcare: GPT-3.5 and 4 excel in clinical reasoning

Sage Ther­a­peu­tics is ter­mi­nat­ing the de­vel­op­ment of its drug dalzanem­dor in Parkin­son’s dis­ease af­ter a mid-stage test end­ed in dis­ap­point­ment. The Phase 2 PRECE­DENT tri­al

Chief ex­ec­u­tives from the three largest phar­ma­cy ben­e­fit man­agers (PBMs) steered around most of the dif­fi­cult ques­tions at a con­gres­sion­al hear­ing, re­peat­ed­ly blam­ing ris­ing pre­scrip­tion